Anita Giobbie-Hurder

Jun 2, 2023 | nature.com | Priscilla K Brastianos |Anita Giobbie-Hurder |Beth Overmoyer |Sara M. Tolaney |Erica L. Mayer

AbstractBrain metastases (BMs) are an emerging challenge in oncology due to increasing incidence and limited treatments. Here, we present results of a single-arm, open-label, phase 2 trial evaluating intracranial efficacy of pembrolizumab, a programmed cell death protein 1 inhibitor, in 9 patients with untreated BMs (cohort A) and 48 patients with recurrent and progressive BMs (cohort B) across different histologies.

Apr 12, 2023 | acsjournals.onlinelibrary.wiley.com | Meghan J. Mooradian |James Cleary |Anita Giobbie-Hurder |Aparna R. Parikh

Abstract Background Combination BRAF and MEK inhibitor therapy is an active regimen in patients who have BRAF V600E-mutated tumors; however, the clinical efficacy of this therapy is limited by resistance. Preclinically, the addition of heat shock protein 90 (HSP90) inhibition improves the efficacy of BRAF inhibitor therapy in both BRAF inhibitor–sensitive and BRAF inhibitor–resistant mutant cell lines.